Annotation Detail
Information
- Associated Genes
- TP53
- Associated Variants
-
TP53 OVEREXPRESSION
(
ENST00000269305.9 )
TP53 OVEREXPRESSION ( ENST00000269305.9 ) - Associated Disease
- stomach cancer
- Source Database
- CIViC Evidence
- Description
- In a Phase II trial of 25 patients with metastaic gastric cancer, patients received preoperative high dose chemotherapy (HDCT) consisting of etoposide, cisplatin and mitomycin. Patients with greater than 50% regression in response to HDCT received surgery. TP53 overexpression was assayed by immunohistochemistry. 14 patients showed p53 overexpression, and 12 of these qualified for resection. Overall survival in patients with p53 overexpression was 17.3 months in contrast to patients with negative p53 immunohistochemistry, where it was 7.2 months (p=0.0003).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2799
- Gene URL
- https://civic.genome.wustl.edu/links/genes/45
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1306
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Stomach Cancer
- Evidence Direction
- Supports
- Drug
- Cisplatin,Etoposide,Mitomycin
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 14514923